

Local Coverage Determination (LCD): MoIDX: APC and MUTYH Gene Testing (L36884)

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

Contractor Information

CONTRACTOR NAME	CONTRACT TYPE	CONTRACT NUMBER	JURISDICTION	STATE(S)
Noridian Healthcare Solutions, LLC	A and B MAC	02101 - MAC A	J - F	Alaska
Noridian Healthcare Solutions, LLC	A and B MAC	02102 - MAC B	J - F	Alaska
Noridian Healthcare Solutions, LLC	A and B MAC	02201 - MAC A	J - F	Idaho
Noridian Healthcare Solutions, LLC	A and B MAC	02202 - MAC B	J - F	Idaho
Noridian Healthcare Solutions, LLC	A and B MAC	02301 - MAC A	J - F	Oregon
Noridian Healthcare Solutions, LLC	A and B MAC	02302 - MAC B	J - F	Oregon
Noridian Healthcare Solutions, LLC	A and B MAC	02401 - MAC A	J - F	Washington
Noridian Healthcare Solutions, LLC	A and B MAC	02402 - MAC B	J - F	Washington
Noridian Healthcare Solutions, LLC	A and B MAC	03101 - MAC A	J - F	Arizona
Noridian Healthcare Solutions, LLC	A and B MAC	03102 - MAC B	J - F	Arizona
Noridian Healthcare Solutions, LLC	A and B MAC	03201 - MAC A	J - F	Montana
Noridian Healthcare Solutions, LLC	A and B MAC	03202 - MAC B	J - F	Montana
Noridian Healthcare Solutions, LLC	A and B MAC	03301 - MAC A	J - F	North Dakota
Noridian Healthcare Solutions, LLC	A and B MAC	03302 - MAC B	J - F	North Dakota
Noridian Healthcare Solutions, LLC	A and B MAC	03401 - MAC A	J - F	South Dakota
Noridian Healthcare Solutions, LLC	A and B MAC	03402 - MAC B	J - F	South Dakota
Noridian Healthcare Solutions, LLC	A and B MAC	03501 - MAC A	J - F	Utah
Noridian Healthcare Solutions, LLC	A and B MAC	03502 - MAC B	J - F	Utah
Noridian Healthcare Solutions, LLC	A and B MAC	03601 - MAC A	J - F	Wyoming
Noridian Healthcare Solutions, LLC	A and B MAC	03602 - MAC B	J - F	Wyoming

LCD Information

Document Information

LCD ID

L36884

Original Effective Date

For services performed on or after 05/15/2017

LCD Title**Revision Effective Date**

MoIDX: APC and MUTYH Gene Testing

For services performed on or after 04/01/2021

Proposed LCD in Comment Period

N/A

Revision Ending Date

N/A

Source Proposed LCD

DL36884

Retirement Date

N/A

AMA CPT / ADA CDT / AHA NUBC Copyright Statement

CPT codes, descriptions and other data only are copyright 2020 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.

Notice Period Start Date

03/30/2017

Notice Period End Date

05/14/2017

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Current Dental Terminology © 2020 American Dental Association. All rights reserved.

Copyright © 2013 - 2020, the American Hospital Association, Chicago, Illinois. Reproduced by CMS with permission. No portion of the American Hospital Association (AHA) copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB-04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312-893-6816. Making copies or utilizing the content of the UB-04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB-04 Manual and/or codes and descriptions; and/or making any commercial use of UB-04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. To license the electronic data file of UB-04 Data Specifications, contact Tim Carlson at (312) 893-6816.

You may also contact us at ub04@aha.org.

CMS National Coverage Policy

Title XVIII of the Social Security Act, §1862(a)(1)(A) allows coverage and payment for only those services that are considered to be reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member.

42 CFR 410.32 Diagnostic x-ray tests, diagnostic laboratory tests, and other diagnostic tests: Conditions

CMS Internet-Only Manual, Pub. 100-02, Chapter 15, §80 Requirements for Diagnostic X-Ray, Diagnostic Laboratory, and Other Diagnostic Tests, §80.1.1 Certification Changes

Coverage Guidance

Coverage Indications, Limitations, and/or Medical Necessity

This policy provides Medicare coverage for APC and MUTYH gene testing for individuals suspected to have Familial Adenomatous Polyposis (FAP), Attenuated FAP (AFAP) or MYH-associated polyposis (MAP) with a personal history of ≥ 20 adenomas over a lifetime.

Summary of Evidence

FAP and AFAP are autosomal dominant syndromes caused by a germline mutation in the adenomatous polyposis coli (APC) gene. The distinction between FAP and AFAP is largely based on the number of polyps present. Individuals with >100 are said to have FAP, while those with <100 are said to have AFAP. FAP affected individuals generally develop adenomas throughout the colon beginning in their teens, whereas individuals with AFAP frequently have a right-sided distribution to polyps. The average age of symptomatic FAP diagnosis ranges from 35-45 years of age.¹ The clinical expression of AFAP is more variable with adenomas developing at a later age, and some patients with <10 cumulative adenomatous polyps.² With nearly 100% penetrance of the APC gene, colorectal cancer (CRC) is inevitable in patients with FAP if colectomy is not performed. The cumulative risk of CRC cancer in AFAP is estimated to be nearly 70% at age 80,³ with up to 30% of cancers occurring over age 40.⁴ The average age of CRC diagnosis is >50 years for AFAP. FAP accounts for up to 1% of colorectal cancers.

Additional findings may be associated with classical FAP including congenital hypertrophy of retinal pigment epithelium (CHRPE); osteomas, supernumerary teeth, and odontomas; desmoids and epidermoid cysts; duodenal and other small bowel adenomas; gastric fundic gland polyps; and increased risk for medulloblastoma, papillary carcinoma of the thyroid and hepatoblastoma; and pancreatic, gastric and duodenal cancers. Although upper gastrointestinal (GI) findings, thyroid and duodenal cancer risks are similar to classical FAP, other extraintestinal manifestations, including CHRPE and desmoids are unusual in AFAP.

Mutations in the MUTYH gene cause MUTYH-Associated Polyposis syndrome (MAP). Affected individuals have large numbers of adenomatous polyp, similar to patient with AFAP, and a high risk for CRC. The average age of patients with MAP-associated CRC is >50 years, with nearly 25% of patients diagnosed after age 60.⁶ Individuals with MUTYH mutations also may develop extra-colonic findings including duodenal polyps and duodenal cancer.

Treatment and surveillance recommendations for FAP, AFAP and MAP are available in the current National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Colorectal guidelines.⁵

Analysis of Evidence (Rationale for Determination)

Level of Evidence:

Quality – High

Strength – Good

Weight - Good

Based on the results of multiple studies and the surveillance and treatment recommendations of at least one national society guideline, APC and MUTYH gene testing is reasonable and necessary for individuals suspected to have Familial Adenomatous Polyposis (FAP), Attenuated FAP (AFAP) or MYH-associated polyposis (MAP) with a personal history of ≥ 20 adenomas over a lifetime.

General Information

Associated Information

N/A

Sources of Information

N/A

Bibliography

1. Jasperson KW, Burt RW. APC-Associated Polyposis Conditions. 1998 Dec 18 [Updated 2014 Mar 27]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2016. <http://www.ncbi.nlm.nih.gov/books/NBK1345/>
2. Burt RW, et al. Genetic testing and phenotype in a large kindred with attenuated familial adenomatous polyposis. *Gastroenterology*. 2004 Aug;127(2):444-51. PubMed PMID: 15300576.
3. Neklason DW, et al. American founder mutation for attenuated familial adenomatous polyposis. *Clin Gastroenterol Hepatol*. 2008 Jan;6(1):46-52. Epub 2007 Dec 11. PubMed PMID: 18063416.
4. Nielsen M, et al. Germline mutations in APC and MUTYH are responsible for the majority of families with attenuated familial adenomatous polyposis. *Clin Genet*. 2007 May;71(5):427-33. PubMed PMID: 17489848.
5. [NCCN® Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Colorectal](#) Accessed 02/10/2021.

Revision History Information

REVISION HISTORY DATE	REVISION HISTORY NUMBER	REVISION HISTORY EXPLANATION	REASON(S) FOR CHANGE
04/01/2021	R7	<p>Under CMS National Coverage Policy updated descriptions and moved regulation CMS Internet-Only Manual, Pub 100-04, Medicare Claims Processing Manual, Chapter 16, §50.5, §60.1.2, §60.2 to the related billing and coding article. Added regulation CMS Internet-Only Manual, Pub. 100-02, Chapter 15, §80 and §80.1.1.</p> <p>Under Bibliography source #5 deleted "Version 1.2016" as this is no longer accessible and updated hyperlink. Formatting, punctuation and typographical errors were corrected throughout the LCD. Acronyms were inserted where appropriate throughout the LCD.</p> <p><i>At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy._</i></p>	<ul style="list-style-type: none"> • Provider Education/Guidance
11/01/2019	R6	<p>The LCD is revised to remove CPT/HCPCS codes in the Keyword Section of the LCD.</p> <p>At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.</p>	<ul style="list-style-type: none"> • Other (The LCD is revised to remove CPT/HCPCS codes in the Keyword Section of the LCD.)
11/01/2019	R5	<p>11/01/2019: This LCD is being revised in order to adhere to CMS requirements per Chapter 13, Section 13.5.1 of the Program Integrity Manual, to remove all coding from LCDs. There has been no change in coverage with this LCD revision.</p>	<ul style="list-style-type: none"> • Provider Education/Guidance

REVISION HISTORY DATE	REVISION HISTORY NUMBER	REVISION HISTORY EXPLANATION	REASON(S) FOR CHANGE
		<p>Regulations regarding billing and coding were removed from the CMS National Coverage Policy section of this LCD and placed in the related Billing and Coding: MoIDX: APC and MUTYH Gene Testing A57353 article.</p> <p>At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage.</p>	
11/01/2019	R4	Related Billing and Coding article to LCD	<ul style="list-style-type: none"> • Revisions Due To Code Removal
11/01/2019	R3	As required by CR 10901, all billing and coding information has been moved to the companion article, this article is linked to the LCD.	<ul style="list-style-type: none"> • Revisions Due To Code Removal
05/15/2017	R2	LCD is revised to add CPT 81401. Note that 81401 was inadvertently left out of the draft and final LCDs.	<ul style="list-style-type: none"> • Creation of Uniform LCDs With Other MAC Jurisdiction
05/15/2017	R1	LCD is revised to add ICD-10 code D12.0, effective 5/12/17 and to add the following required fields: Summary of Evidence, Bibliography and Analysis of Evidence.	<ul style="list-style-type: none"> • Creation of Uniform LCDs Within a MAC Jurisdiction • Revisions Due To ICD-10-CM Code Changes

Associated Documents

Attachments

N/A

Related Local Coverage Documents

Article(s)

A57353 - Billing and Coding: MoIDX: APC and MUTYH Gene Testing

A55464 - Response to Comments: MoIDX: APC and MUTYH Gene Testing

LCD(s)

DL36884

- (MCD Archive Site)

Related National Coverage Documents

N/A

Public Version(s)

Updated on 03/22/2021 with effective dates 04/01/2021 - N/A

Updated on 01/29/2020 with effective dates 11/01/2019 - 03/31/2021

Updated on 12/03/2019 with effective dates 11/01/2019 - N/A

Updated on 10/07/2019 with effective dates 11/01/2019 - N/A

Updated on 10/07/2019 with effective dates 11/01/2019 - N/A

Some older versions have been archived. Please visit the MCD Archive Site to retrieve them.

Keywords

N/A